Loading view.
Latest Past Events
Taking Aim With the Next Wave of Antibody–Drug Conjugates in NSCLC: Rational Strategies for Addressing the Unmet Needs of Diverse Patient Populations With TROP2- and HER3-Targeting Therapies and Other ADC-Based Regimens
Hall 406
Sponsored by PeerView Institute for Medical Education
Supported by an educational grant from Daiichi Sankyo, Inc.
Taking Aim at HER2-Driven NSCLC
Hall 406
Sponsored by Daiichi Sankyo and AstraZeneca
Tackling Unmet Needs for Patients with NSCLC: Latest Scientific Advances & Investigational Approaches
Hall 405B
Sponsored by GSK